Figure 1From: The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014 Ipilimumab clinical activity (OS) irrespective of BRAF mutational status: the Italian EAP in melanoma by Ascierto et al. J Trans Med 2014; 12: 116–122 [[26]]. Back to article page